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The present study was undertaken to examine the long-term hematological 
and histopathoiogical effects of the administration of very large doses  of the 
heme oxygenase inhibitor, Sn-protoporphyrin, in genetically mutant mice with 
hemolytic anemia (sphha/sphha).  The study was prompted by the potential for 
clinical use of this enzyme inhibitor to suppress severe neonatal hyperbilirubi- 
hernia in humans. This condition is currently treated principally by phototherapy 
and by exchange transfusions (1) but these treatments are not without drawbacks 
(1).  Moreover,  these  modalities of therapy are  directed towards the complex 
problem of disposing of bilirubin after, rather than before, it has been formed 
in the heme oxidation system. 
In contrast, in previous studies from this laboratory (2,  3), we have proposed 
the idea that it might be possible,  by using the heme oxygenase inhibitor Sn- 
protoporphyrin, to inhibit the formation of bilirubin, thus approaching severe 
neonatal hyperbilirubinemia in a chemopreventive manner. Among a series of 
related compounds that we examined, Sn-protoporphyrin was not only the most 
potent inhibitor in vitro of the activity of microsomal as well as homogenously 
purified heine oxygenase (2-4),  but could also suppress hyperbilirubinemia in 
the rat neonate (2, 3) and in various forms of naturally occurring or experimen- 
tally induced jaundice in animals and man (5, 6). 
Since  Sn-protoporphyrin has  not,  in  our  studies,  been  associated  with any 
significant toxicity after its acute administration in animals or man, we felt it 
important to investigate the long-term effects of large amounts of this metallo- 
porphyrin in genetically anemic mutant mice with hemolytic anemia (sphha/sphha), 
a  disease in which very severe hemolysis and excessive hyperbilirubinemia are 
conspicuous features. The results of this study confirm no apparent toxic effects 
of Sn-protoporphyrin over 8  mo, in a  marginally viable strain of mutant mice 
with profound hemolytic anemia. 
Materials and Methods 
Mice.  The  mutant  mice  used  in  this  study  were  animals  with  hemolytic  anemia 
(WBB6F~-sphha/sph ~)  produced  by  mating  heterozygotes  from  two  different inbred 
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strains,  WB/Re and C57BL/6J, reared at The Jackson  Laboratory. The origin of the 
mutant  and  its  pathophysiological characteristics  have  been  described  previously (7). 
Animals were housed under conditions approved by the American Association of Labo- 
ratory Animals Center and fed Purina Lab Chow and water ad lib. Animals used were of 
both sexes and were aged 8-10 mo, except in the 32-wk study in which 4-mo-old animals 
were used. Because of the extreme rarity of this strain of mice, experimental groups could 
not be large (two animals per data point; seven animals in each group in the 32-wk study) 
and statistical analysis of data was not performed unless it was applicable. 
Sample Preparation.  Blood was obtained from the retroorbitai sinus  for the determi- 
nation of plasma bilirubin, Sn-protoporphyrin, and free erythrocyte protoporphyrin, as 
well as activities of &aminolevulinate (ALA)  ~ dehydratase and porphobilinogen (PBG) 
deaminase.  Mice  were  killed  by  cervical dislocation.  Liver,  kidney,  and  spleen  were 
removed for the isolation of microsomes and the determination of cytochrome P-450 and 
heme oxygenase activity. 
For histochemical studies, tissues were fixed in Tellyesniczky's fixative (formalin/acetic 
acid/alcohol) for 24 h before paraffin imbedding and sectioning at 7 #m. Sections were 
stained with hematoxylin and eosin. 
Assays.  Erythrocyte protoporphyrin, ALA dehydratase activity, and PBG deaminase 
activity were determined as described previously (8). ALA synthase activity and micro- 
somal heme oxygenase activity was assayed as described previously (9). Cytochrome P- 
450 was determined according to the method of Omura and Sato (10). Sn-protoporphyrin 
concentration was  determined by a  fluorometric method developed in  our laboratory 
(11).  Plasma  bilirubin concentrations were quantified after the  method of Roth  (12). 
Fluorometric determinations (for free erythrocyte protoporphyrin, Sn-protoporphyrin, 
plasma bilirubin, and PBG deaminase activity) were made using a Hitachi/Perkin-Elmer 
MPF 4 fluorescence spectrophotometer (Perkin-Elmer Corp., Instrument Div., Norwalk, 
CT) equipped with a R928 photomultiplier (9). The instrument was calibrated daily with 
0.1 ~M coproporphyrin III in 0.14 N HCI. 
Sn-protoporphyrin.  Sn-protoporphyrin (Porphyrin Products, Logan, UT) was dissolved 
in 0.5 N NaOH and diluted with 0.9% NaC1 as described previously (14). The pH of the 
solution  was  adjusted  to  ~8  with  0.5  N  HCI  before subcutaneous  injection.  Control 
animals received an equivalent volume of vehicle prepared without Sn-protoporphyrin. 
Results 
Accumulation  of Sn-protoporphyrin  in the Liver and Kidney.  Sn-protoporphyrin 
concentrations were determined fluorometricalty in homogenates from the liver 
and kidney in sph~/sph h" mice 2  wk after the first injection. Sn-protoporphyrin 
content in  both organs  increased proportionately with  increasing  doses of the 
compound (Fig. 1). Repeated administration of 100 umol/kg body weight caused 
marked tissue accumulation. The spleen accumulated lower concentrations than 
the other two organs,  e.g., one-fifth of the concentration in the liver (data not 
shown). 
Effects  of Sn-protoporphyrin  on  Heine  Oxygenase  Activity.  The  levels of heme 
oxygenase activity in sphh~/sph ~  mice were examined after treatment  with Sn- 
protoporphyrin. Animals were injected subcutaneously on day 0 with saline and 
either 10 ~mol/kg or 100 ~mol/kg Sn-protoporphyrin or five consecutive daily 
doses, subcutaneously, of 100 #mol/kg body weight of Sn-protoporphyrin. They 
were then sacrificed on day  14. As shown in Fig.  2, heme oxygenase activity in 
the  liver, spleen, and  kidney was decreased in a  dose-dependent manner.  Five 
1  Abbreviations used in this paper:  ALA,  6-aminolevulinate;  MCH, mean corpuscular hemoglobin; 
MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; PBG, por- 
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FIGURE  1.  Tissue concentration of Sn-protoporphyrin. 8-mo-old female animals were used. 
Animals were treated with saline plus 10 or 100 ~tmol/kg Sn-protoporphyrin on day 0 or five 
consecutive daily doses of 100/zmol/kg Sn-protoporphyrin and sacrificed on day  14. Tissue 
concentration of the metalloporphyrin was determined fluorometrically as described in the 
text. Data are the mean of duplicate determinations for two animals for each point. Variations 
between two animals were within 15% of the mean. 
injections each  of 100 #mol/kg  Sn-protoporphyrin  resulted  in  ~80,  -70,  and 
~90%  suppression  of heme oxygenase activity in the liver,  spleen, and  kidney, 
respectively. 
Effect of Sn-protoporphyrin  on Plasma Bilirubin Concentrations.  Fig. 3 shows the 
effect of Sn-protoporphyrin  (100  gmol/kg  body weight,  s.c.,  once weekly) on 
bilirubin and Sn-protoporphyrin concentrations in plasma in sphha/sph ^a mice for 
a total of 16 wk. Plasma Sn-protoporphyrin concentration increased progressively 
during  the  treatment.  In  contrast,  bilirubin  concentration  was  decreased  to 
~50%  2  wk after treatment  and  remained  at approximately  that  level for the 
full period of study. 
Dose-Response  Effects  of Sn-protoporphyrin  on Plasma Bilirubin  Levels.  In  the 
course of this study, we observed that average plasma bilirubin  levels in sphha/ 
sph  ha mice varied from  2.0 to 3.7  mg/dl  depending  on their age, sex, housing 
conditions,  and  perhaps  other  unknown  factors.  However,  the  coefficient of 
variation in bilirubin concentration within the same sex from the same littermates 
was  always  very  small  (within  5%  of the  mean);  thus,  all  experiments  were 
performed  using  animals  of the  same  sex  from  the  same  litter  housed  under 
identical conditions.  Table I shows the effect of variable doses of Sn-protopor- 
phyrin on plasma bilirubin levels 3 d after injection. Plasma bilirubin decreased 
proportionately with the increase in the dose of Sn-protoporphyrin. 
Effects of Sn-protoporphyrin  on Erythrocyte Heme Pathway Enzymes and Protopor- SASSA  ET  AL.  867 
5 
4 
3 
2 
1 
a  0 
3 
2 
10 
0 
Liver 
~  Spleen 
Kidney 
0  10  100  5xlQO 
Sn-protol0orptwrin (,umol/kg ) 
FIGURE 2.  Effect of Sn-protoporphyrin on microsomal heme oxygenase activity. 8-mo-old 
female mice (sph~/sph  ~) were used. Animals were treated as described in the legend to Fig. 
1.  Heme oxygenase activity was determined using duplicate microsomal samples prepared 
from two livers or two spleens and four kidneys for each point, as described in the text. 
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FIGURE 3.  Effect of Sn-protoporphyrin on plasma bilirubin concentrations. 8-mo-old female 
animals were used. Animals were treated with Sn-protoporphyrin (100  t~g/kg  body weight, 
s.c.) once weekly during the experimental period. Blood specimens were collected from the 
orbital sinus without sacrificing the animals. Bilirubin and Sn-protoporphyrin concentrations 
were determined fluorometrically as described in Materials and Methods. It has been shown 
previously (2, 11) that the two fluorometric assays do not interfere with each other. Each point 
represents the mean of two mice. Variations between two animals were within  15%  of the 
mean. 868  SUPPRESSION  OF  HYPERBILIRUBINEMIA 
TABLE  I 
Dose-Response Effect of Sn-protoporphyrin on Plasma Bilirubin 
Concentration 
Sn-protopor-  No. of injec-  Plasma bilirubin 
phyrin  tions 
#mol/kg  mg/dl 
0  --  3.61  -  0.15 
10  1  3.14 --- 0.67 NS 
100  1  2.43 +  0.37 (P< 0.01) 
100  3  1.87 +  0.21 (P <  0.001) 
10-mo-old male sph~/sph  ~ mice were used for study. Sn-protoporphyrin 
was injected subcutaneously on day 0. The last group received Sn-proto- 
porphyrin injections once daily on days 0,  1, and 2. Plasma bilirubin was 
determined on day 3 (72 h after the first injection) as described in Materials 
and Methods. Data are the mean of four determinations using two mice. 
NS, not significant. 
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FIGURE 4.  Effects of Sn-protoporphyrin on the activity of ALA synthase, ALA dehydratase, 
and PBG deaminase in erythrocytes. 8-too-old female animals were used. Animals were treated 
as described in the legend to Fig.  1.  Enzyme assays  were carried out using whole blood, as 
described  in  Materials and  Methods.  Each  point represents  the  mean  of duplicate assays. 
Variations between the two animals were within 10% of the mean. 
phyrin  Concentrations.  Effects  of  Sn-protoporphyrin  on  the  activities  of heme 
pathway  enzymes  and  protoporphyrin  concentrations  in  erythrocytes  were  also 
examined.  As shown  in Fig. 4, Sn-protoporphyrin  treatment  did not significantly 
alter  the activities of ALA  synthase,  ALA  dehydratase,  and  PBG  deaminase,  or 
the concentration  of erythrocyte  protoporphyrin. SASSA  ET  AL.  869 
Effects of Sn-protoporphyrin on Heme Pathway Enzymes and Cytochrome P-450 in 
the Liver and the Kidney.  Fig. 5A shows the effect of Sn-protoporphyrin  on the 
activities of ALA synthase,  ALA dehydratase,  and  PBG deaminase in the liver 
of sph~/sph  h~ mice. Sn-protoporphyrin  treatment slightly decreased ALA dehy- 
dratase activity in the liver in a dose-dependent manner,  while PBG deaminase 
activity was decreased slightly only at the two higher doses. Hepatic ALA synthase 
was  suppressed  -40%  by  all  three  doses.  The  observed  decreases  in  heme 
pathway  enzymes  did  not  appear  to  have  significant  consequences  for  heme 
formation in the liver and kidney since cytochrome P-450 content in both tissues 
remained unaffected by Sn-protoporphyrin treatment (Fig. 5B). 
Sn-protoporphyrin Disappearance  from Plasma.  Sn-protoporphyrin was fluoro- 
metrically detectable in plasma within  1 h of its injection. It had a characteristic 
fluorescence emission spectrum (maxl  =  581  nm; max2 =  635 nm) in a mixture 
of N-perchloric acid/methanol (1:1 vol/vol), thus permitting its sensitive detection 
in  the  presence  of other  porphyrins  (11).  Sn-protoporphyrin's  disappearance 
from plasma involved complex kinetics, with an initial  half-life of 4 h, followed 
by increased half-lives of 12 h  and  3 d  as the plasma level declined to very low 
levels (Fig. 6). 
Effect of  Sn-protoporphyrin on Hematological Indices.  The effects on hematolog- 
ical  indices  of  Sn-protoporphyrin-  and  vehicle-treated  sphha/sph  ha  mice  were 
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Effects of Sn-protoporphyrin on heine pathway enzymes and cytochrome P-450 
content. (A) ALA synthase, ALA dehydratase, and PBG deaminase in the liver. (B) Cytochrome 
P-450 in the liver and the kidney. Animals were treated as described in the legend to Fig. 1. 
Enzyme assays and cytochrome P-450 determinations  were carried out as described  in Materials 
and Methods. Data are the mean of two mice. 870  SUPPRESSION  OF  HYPERBILIRUB1NEMIA 
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FIGURE  6.  Sn-protoporphyrin disappearance  from plasma. Plasma Sn-protoporphyrin con- 
centration was determined fluorometrically (11) after a single injection of 100 #mol/kg body 
weight, s.c. Data are the mean of duplicate determinations for each of two 8-mo-old female 
mice. 
TABLE  II 
Effects of Sn-protoporphyrin on Hematological Indices in sphha/sph  ~ Mice 
Hematological 
index 
Vehicle  Sn-protoporphyrin 
Pretreat-  Posttreat-  Pretreat-  Posttreat-  12 wk  12 wk  ment  merit  ment  ment 
RBC (Xl0~/liter)  4.80 ± 0.46  4.29 ± 0.09  4.40 ± 0.34  4.85 ± 0.08 
Hematocrit (%)  27.3 ±  1.75  25.9 ± 0.53  24.5 ±  1.58  27.6 ± 0.39 
MCV (u  3)  57.0 ± 2.60  60.23 ± 0.67  55.9 ± 5.7  57.0 ± 0.68 
Hemoglobin (g/dl)  6.36 ± 0.54  6.00 ± 0.12  5.70 ± 0.40  6.53 ± 0.17 
MCHC (g/dl)  23.3 +  1.68 23.21 + 0.25  23.3 ±  1.58  23.7 ± 0.46 
Protoporphyrin  980 ±  140  971 ___ 39  1,015 ± 46  1,023 ± 38 
(/zg/dl RBC) 
Reticulocytes (%)  94.5 ± 0.9  96.3 ± 0.2  97.4 ±  1.8  93.8 ±  1.3 
4.62±0.14  4.70±0.23 
26.1±0.63  26.4±2.69 
56.6±1.33  56.2±4.64 
6.01±0.14  5.70±0.48 
23.0±0.36  21.6±0.63 
1,042±29  960±101 
96.8±0.4  98.2±1.0 
Seven mice (4 mo old) in each group were treated with vehicle or Sn-protoporphyrin (100 t~mol/kg, s.c., 
once weekly) for up to 32 wk. Data shown for posttreatment are hematological indices (mean _  SE) 1 wk 
after the last injection.  Weekly hematological  examinations during the treatment period did not show 
significant changes between the vehicle-treated control and Sn-protoporphyrin-treated  animals. 
determined at  regular intervals during the  32  wk  of treatment (100  #mol/kg 
body  weight,  s.c.,  once  weekly).  Each  group  consisted  of seven  female  mice. 
Results are shown for the pretreatment, treatment, and the posttreatment periods 
(Table II). There were small, age-dependent changes in most of the hematological 
indices in both  vehicle-treated control and Sn-protoporphyrin-treated animals. 
Both  groups  of animals showed  similar hematological  values characteristic  of 
mice  with  this  severe  chronic  form  of  hemolytic  disease.  Sn-protoporphyrin 
treatment had no significant effects on hematological indices (Table II). 
Organ  Weights and Histopathology  of sphh~/sph ha Mice  Treated  with Sn-protopor- 
phyrin.  Table III shows the effects on organ weights, gall stones, and histopa- 
thoiogy  of vehicle-treated  controls  and  mice  treated  with  Sn-protoporphyrin 
(100  /lmol/kg  body  weight,  s.c.,  once  weekly)  for  32  wk.  There  were  no SASSA  ET  AL. 
TABLE  III 
Long-term Effects of Sn-protoporphyrin on Organ Weights and Histopathology 
871 
Organ weight after treatment with: 
Vehicle  Sn-protoporphyrin 
Percent of body  Percent of body  Mean 4- SE  Mean +  SE  weight  weight 
g  %  g  % 
Body wt.  28.05 4- 0.61  100  28.84 _  0.76  100 
Liver  2.24 4- 0.09  7.99  2.68 4- 0.12  9.29 (P <  0.02) 
Spleen  1.39 +  0.02  4.96  1.34 _  0.11  4.64 NS 
Kidney  0.36 4- 0.01  1.28  0.44 4- 0.02  1.53  (P <  0.02) 
Femur  0.09 4- 0.002  0.32  0.09 4- 0.003  0.31  NS 
Gall stones (#g/  175  140 
mouse) 
Seven mice (4 mo old) in each group were treated with vehicle or Sn-protoporphyrin (100 #mol/kg, 
s.c., once weekly) for 32 wk. Animals were sacrificed 1 wk after the last injection and organ weights 
were examined. NS, not significant. 
differences in  body weights, spleen sizes,  or femur sizes  between control and 
experimental groups.  By contrast, there were increases of a  low order of mag- 
nitude in liver size and kidney size (expressed as the organ weight as percent of 
total  body  weight)  after  prolonged  Sn-protoporphyrin  treatment.  Average 
weights of gall stones were smaller (~20%) in Sn-protoporphyrin-treated animals 
than in  controls; however, no statistical comparison could be made since gall- 
stones had to be pooled for each group for determination of their dry weights. 
Representative figures for gall bladders containing stones are shown in  Fig.  7 
for each group. 
Histopathological examinations revealed many well-demarcated orange-brown 
pigment concretions within  cell  clusters  in  the  liver  in  both  control  and  Sn- 
protoporphyrin-treated groups (Fig. 8A). Many highly active hematopoietic foci 
were present in the liver in both groups of animals. Spleens from both groups 
showed many scattered pigment granules and large black concretions (Fig. 8B). 
Kidneys also contained massive orange inclusions in the tubules but none in the 
medulla or in the glomerulae (Fig. 8 C). Bone marrow and skin samples appeared 
generally normal  in  both  groups  of animals  (Fig.  8D).  The  massive pigment 
granules in the liver, spleen, and kidney were typical of those found in severely 
hemolytic animals and there were no significant histopathological changes spe- 
cifically attributable to treatment with Sn-protoporphyrin. 
Discussion 
The  hemolytic anemic mutant mouse (sphha/sph h~) represents an  extremely 
useful model system for the study of hyperbilirubinemia since, in this mutant, 
red cell survival time is <1.5 d, compared with ~60 d in normal control animals 
(8).  As  a  consequence, affected homozygotes have  markedly elevated  serum 
bilirubin levels (13,  14). These animals also have markedly decreased hemoglo- 
bin,  hematocrit, mean corpuscular hemoglobin (MCH), and mean corpuscular 
hemoglobin concentration (MCHC) and greatly elevated reticulocyte levels in 872  SUPPRESSION  OF  HYPERBILIRUBINEMIA 
FIGURE 7.  Gall bladders from sph~/sph ~  mice. (A) Gall bladder from a  mouse (12-mo-old 
female)  treated  with  vehicle for  32  wk.  (B)  Gall  bladder  from  a  mouse  treated  with  Sn- 
protoporpbyrin (100 #mol/kg body weight, once weekly) for 32 wk. 
their  circulation  (~90%  of red  cells  are  reticulocytes). They also  display  an 
increased incidence of calcium bilirubinate gallstones as they age (15). 
Our data on plasma bilirubin levels over  16  wk demonstrated that excessive 
hyperbilirubinemia in the affected homozygotes can be substantially decreased 
by Sn-protoporphyrin treatment. Sn-pr.otoporphyrin also markedly suppressed SASSA ET  AL.  873 
FIGURE 8.  Histopathology of  organs from sphh*/sph h" mice. Control: mice  (12-mo-old  female) 
treated with vehicle for 32 wk. Sn-protoporphyrin: mice treated with Sn-protoporphyrin (100 
ttmol/kg body weight) for 32 wk. Both groups showed orange concretions in the liver, kidney, 
and spleen that are due to their hemolytic disease. There are no obvious histopathological 
changes attributable to Sn-protoporphyrin treatment. 
the activity of heme oxygenase in the liver, spleen, and kidney, while it did not 
significantly affect the  enzymes in  the  heme  biosynthetic pathway  in  the  liver 
(Fig. 5), kidney (data not shown), spleen (data not shown), and erythrocytes (Fig. 
4). Inhibition of heme oxygenase activity in the liver and the kidney did not have 
deleterious effects on the level of cytochrome P-450  in either organ (Fig.  5B). 
It is clear from these studies that continuous treatment with a  large dose of Sn- 
protoporphyrin does not appreciably interfere with heme synthesis in erythroid 
cells, liver, and kidney, but does, in confirmation of earlier data (2, 3, 5, 6,  16), 874  SUPPRESSION  OF  HYPERBILIRUBINEMIA 
significantly suppress heme oxygenase activity and plasma bilirubin concentra- 
tion. 
Sn-protoporphyrin has been shown to  inhibit  the activity of purified heme 
oxygenase (4) and heme oxygenase activity in microsomal preparations in vitro 
(2,  3).  It  also  inhibits  hepatic,  splenic,  and  renal  heine oxygenase activity in 
neonatal rats (2, 3), suppresses biliary bilirubin output derived from endogenous 
or exogenous heme sources (17), and substantially diminishes carbon monoxide 
production that results from the catabolism of endogenous and exogenous heine 
(18). These findings, together with those in the present study, confirm that this 
synthetic heme analogue inhibits  heine oxidation  in  vivo  (2,  3),  even  under 
markedly elevated conditions of bile pigment production. 
When administered in vivo, Sn-protoporphyrin appears to be retained in tissues 
for considerable periods of time. The major portion of the plasma Sn-protopor- 
phyrin was cleared with a  half-life of 4  h  (Fig.  6),  while tissues  such as liver, 
kidney (Fig.  1), and spleen accumulate the metalloporphyrin in a dose-dependent 
manner (19).  Tissue accumulation of Sn-protoporphyrin for extended periods 
(detectable up to 2 wk after a single injection of 100 umol/kg) can be explained 
in part by the fact that the metalloporphyrin cannot be oxidatively degraded by 
the  microsomal  heme  oxygenase  system  (4).  Long-term  inhibition  of  heme 
oxygenase activity (up to 3 wk) after a  single injection of Sn-protoporphyrin is 
also probably due to  the metabolically stable  nature of the metalloporphyrin. 
These data suggest that only a single injection may control hyperbilirubinemia 
in circumstances when excessive levels of this bile pigment may have a neurotoxic 
potential, as in a severely  jaundiced premature infant. 
Long-term treatment (32 wk) of 4-mo-old sphh~/sph h~ mice with a  very large 
dose of Sn-protoporphyrin (100  gmoi/kg body weight), once weekly (total  of 
3,200 umol) revealed no toxicity on erythroid, hepatic, and renal heme pathway 
enzymes. Hematological indices such as erythrocyte count, hemoglobin concen- 
tration,  mean corpuscular volume (MCV),  MCH,  MCHC,  reticulocyte count, 
granulocyte count, and platelet count were identical for vehicle-treated control 
and Sn-protoporphyrin-treated animals. Histopathological examinations of these 
tissues also demonstrated no pathological changes attributable to Sn-protopor- 
phyrin. Treatment of mutant mice suffering a still more severe form of inherited 
hemolytic anemia, ja/ja,  all of whom die within 10 d of birth, also did not reveal 
any sign of increased toxicity (data not shown). 
In  mice treated  with  Sn-protoporphyrin,  the  "free" heme concentration in 
liver cells may be increased as a consequence of the inhibition of heine oxygenase. 
A recent study from our laboratory (20) has, in fact, shown that an increase in 
free heine concentration occurs in the liver after Sn-protoporphyrin treatment, 
since the extent of heme saturation of hepatic tryptophan pyrrolase increases 
rapidly and markedly after Sn-protoporphyrin treatment. Excessive heme accu- 
mulation, however, does not occur, since it has also been established (21) that 
heme is rapidly excreted into the bile of rats when heme oxygenase is inhibited 
by Sn-protoporphyrin. We conclude that any transient cellular increases in heme 
concentration that may occur after Sn-protoporphyrin treatment do not have 
significant hematological consequences, even in animals, such as sphh"/sph h" mice, 
that are marginally viable. SASSA ET  AL.  875 
This study confirms the nontoxic  nature of Sn-protoporphyrin  administered 
over a prolonged period of time and in very high doses to the sph~/sph ha anemic 
mutant  mouse,  in  which  heme  breakdown  is  far  greater  than  that  in  man.  It 
extends  our  earlier  findings  on  Sn-protoporphyrin-mediated  suppression  of 
hyperbilirubinemia  in  genetically hemolytic anemic mice (14).  On the basis of 
these and our previous findings, the Sn-protoporphyrin may prove to be a useful 
compound for the management  of hyperbilirubinemia  in selected cfinical situa- 
tions,  since humans  would require  much  smaller  doses, e.g.,  0.5-1.0  #mol/kg 
body weight (6),  to suppress hyperbilirubinemia  than  those used in the present 
experiments. 
Summary 
The  effects of long-term  administration  of very large doses of Sn-protopor- 
phyrin  on  hematological  indices,  histological  changes,  plasma  bilirubin  levels, 
tissue heme oxygenase activity, and activities of heme biosynthetic enzymes, were 
examined in genetically anemic mutant mice with hemolytic anemia (sphh"/sphha). 
Long-term weekly treatment with Sn-protoporphyrin (100 #mol/kg body weight 
for 32 wk) did not alter hematological  indices, histological findings,  or enzyme 
activities  related  to  heme  biosynthesis,  even  though  it  resulted  in  sustained 
decreases in microsomal heine oxygenase activity in the liver, kidney, and spleen, 
and a prolonged decrease in plasma bilirubin concentration.  Inhibition of heme 
oxygenase did not alter the level of cytochrome P-450 in the liver and the kidney. 
The  results indicate  that  long-term  treatment  with massive doses of Sn-proto- 
porphyrin  suppresses bilirubin  formation  but does not produce significant  his- 
topathological changes or appreciably interfere with heme synthesis, in this strain 
of genetically anemic mice. These findings provide further support for the idea 
that suppression of heme degradation to bile pigment by the inhibition of heine 
oxygenase may prove useful to the prevention  of severe hyperbilirubinemia  in 
humans. 
Received for publication  21 March 1985. 
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